Sensus Healthcare Inc (SRTS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.19-2.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue at or above $27.5 million in FY26: FY26 guidance $0.0M vs $27.5M target.
Sensus Healthcare aims to grow revenue above $27.5 million in 2026. The company has a new credit facility to support operations. Analysts expect revenue growth of about 31% next year. The stock trades at a low price-to-sales ratio compared to peers.
The company is loss-making and EPS estimates are negative through 2027. Recent earnings misses and legal/regulatory changes raise concerns. Revenue growth and profitability may not recover as hoped.
The market price reflects a 31% revenue growth expectation and is about 54% below our valuation range. Our view aligns with the market on growth but remains cautious on profitability risks.
Breaks if: Loss of credit facility or liquidity crisis
Breaks if: EPS remains below -$0.02 per share in FY27
Breaks if: Revenue falls below $27.5 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving customer adoption and expanding recurring revenue. The current thesis state is cautious, as recent financial results have been below industry standards, but there are signs of potential growth in specific areas.
The market appears to have priced in a level of fragility due to weak execution quality, but not to the extent of a full negative outlook. The valuation is aligned with peers, suggesting that expectations are somewhat low, yet there is a premium compared to others in the sector.
Fundamentals may remain weak in the near term, as there is a high probability of an earnings miss. Management is focused on driving customer adoption and expanding revenue streams, but recent performance has not yet reflected these efforts.
The long-term thesis hinges on management's ability to execute on their priorities, particularly in driving customer adoption and expanding recurring revenue. Additionally, external factors such as sector performance and economic conditions will play a significant role in the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company can leverage new CPT codes. This will improve reimbursement and sales. It also reported strong earnings, beating expectations. The company is targeting a higher average selling price. This supports customer adoption and growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, SRTS must navigate its current challenges while leveraging potential growth opportunities. Not investment advice.